The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Drug discovery in the ubiquitin–proteasome system
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Mechanisms Underlying Ubiquitination
Pickart, C. M. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.503 · Cited by 3,184
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., & Howley, P. M. (1993) · Cell · doi:10.1016/0092-8674(93)90384-3 · Cited by 2,054
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
Structure of ubiquitin refined at 1.8 Å resolution
Vijay-kumar, S., Bugg, C. E., & Cook, W. J. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90679-6 · Cited by 1,742
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., & Nakayama, K.-I. (1996) · Cell · doi:10.1016/s0092-8674(00)81237-4 · Cited by 1,547
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein
Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., & Varshavsky, A. (1989) · Science · doi:10.1126/science.2538923 · Cited by 1,535
Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex
Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., et al. (2002) · Nature · doi:10.1038/416703a · Cited by 1,507
Self-citationFero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
UBE3A/E6-AP mutations cause Angelman syndrome
Kishino, T., Lalande, M., & Wagstaff, J. (1997) · Nature Genetics · doi:10.1038/ng0197-70 · Cited by 1,298
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27
Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., & Koff, A. (1996) · Cell · doi:10.1016/s0092-8674(00)81238-6 · Cited by 1,251
Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
Hershko, A., Heller, H., Elias, S., & Ciechanover, A. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82050-x · Cited by 1,160
Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001) · Science · doi:10.1126/science.1060627 · Cited by 1,053
A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase.
Huibregtse, J. M., Scheffner, M., Beaudenon, S., & Howley, P. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2563 · Cited by 1,013
Role of Rpn11 Metalloprotease in Deubiquitination and Degradation by the 26 S Proteasome
Verma, R., Aravind, L., Oania, R., McDonald, W. H., Yates, J. R., Koonin, E. V., & Deshaies, R. J. (2002) · Science · doi:10.1126/science.1075898 · Cited by 1,000
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
Self-citationWelcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04990.x · Cited by 879
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome
Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R.-J., Jiang, Y.-H., Benton, C. S., Rommens, J. M., & Beaudet, A. L. (1997) · Nature Genetics · doi:10.1038/ng0197-74 · Cited by 856
The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation
Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M., & Cyr, D. M. (2001) · Nature Cell Biology · doi:10.1038/35050509 · Cited by 839
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Molecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740
Nakayama, K. (2000) · The EMBO Journal · doi:10.1093/emboj/19.9.2069 · Cited by 717
Systematic analysis and nomenclature of mammalian F-box proteins
Jin, J., Cardozo, T., Lovering, R. C., Elledge, S. J., Pagano, M., & Harper, J. W. (2004) · Genes & Development · doi:10.1101/gad.1255304 · Cited by 712
Self-citationGenetics of Parkinson disease: paradigm shifts and future prospects
Farrer, M. J. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1831 · Cited by 707
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Role of Predicted Metalloprotease Motif of Jab1/Csn5 in Cleavage of Nedd8 from Cul1
Cope, G. A., Suh, G. S. B., Aravind, L., Schwarz, S. E., Zipursky, S. L., Koonin, E. V., & Deshaies, R. J. (2002) · Science · doi:10.1126/science.1075901 · Cited by 691
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Hershko, A., Ciechanover, A., & Varshavsky, A. (2000) · Nature Medicine · doi:10.1038/80384 · Cited by 649
Structure of a β-TrCP1-Skp1-β-Catenin Complex
Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W., & Pavletich, N. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00234-x · Cited by 612
Self-citationU Box Proteins as a New Family of Ubiquitin-Protein Ligases
Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N., & Nakayama, K.-I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102755200 · Cited by 579
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity
Xirodimas, D. P., Saville, M. K., Bourdon, J.-C., Hay, R. T., & Lane, D. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.016 · Cited by 570
Structure of an E6AP-UbcH7 Complex: Insights into Ubiquitination by the E2-E3 Enzyme Cascade
Huang, L., Kinnucan, E., Wang, G., Beaudenon, S., Howley, P. M., Huibregtse, J. M., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.286.5443.1321 · Cited by 562
Ciechanover, A., Heller, H., Elias, S., Haas, A. L., & Hershko, A. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1365 · Cited by 562
Inactivation of hCDC4 can cause chromosomal instability
Rajagopalan, H., Jallepalli, P. V., Rago, C., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2004) · Nature · doi:10.1038/nature02313 · Cited by 551
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Pavletich, N. P., Chambers, K. A., & Pabo, C. O. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2556 · Cited by 521
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation
Huang, H., Regan, K. M., Wang, F., Wang, D., Smith, D. I., van Deursen, J. M. A., & Tindall, D. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406789102 · Cited by 518
Skp2 is oncogenic and overexpressed in human cancers
Gstaiger, M., Jordan, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J., & Krek, W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081474898 · Cited by 505
Iwakuma, T., & Lozano, G. (2003) · PubMed · Cited by 503
Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase
Bornstein, G., Bloom, J., Sitry-Shevah, D., Nakayama, K., Pagano, M., & Hershko, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301774200 · Cited by 494
Wei, N., & Deng, X. W. (2003) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.19.111301.112449 · Cited by 491
Imai, Y., Soda, M., Hatakeyama, S., Akagi, T., Hashikawa, T., Nakayama, K.-I., & Takahashi, R. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00583-x · Cited by 473
Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300
Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., & Livingston, D. M. (2003) · Science · doi:10.1126/science.1080386 · Cited by 459
Pickart, C. M. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01681-9 · Cited by 454
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
Hemann, M. T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J. A., Cordon-Cardo, C., Cleveland, J. L., Tansey, W. P., & Lowe, S. W. (2005) · Nature · doi:10.1038/nature03845 · Cited by 452
Verma, R., Oania, R., Graumann, J., & Deshaies, R. J. (2004) · Cell · doi:10.1016/j.cell.2004.06.014 · Cited by 449
Latres, E., Chiaur, D. S., & Pagano, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202653 · Cited by 443
Pesah, Y., Pham, T., Burgess, H., Middlebrooks, B., Verstreken, P., Zhou, Y., Harding, M., Bellen, H., & Mardon, G. (2004) · Development · doi:10.1242/dev.01095 · Cited by 443
Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines
Moberg, K. H., Bell, D. W., Wahrer, D. C. R., Haber, D. A., & Hariharan, I. K. (2001) · Nature · doi:10.1038/35095068 · Cited by 438
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu
Xu, W., Marcu, M., Yuan, X., Mimnaugh, E., Patterson, C., & Neckers, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202365899 · Cited by 433
Prophylactic human papillomavirus vaccines
Lowy, D. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28607 · Cited by 428
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., & Deshaies, R. J. (2003) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t300009-mcp200 · Cited by 425
The U box is a modified RING finger — a common domain in ubiquitination
Aravind, L., & Koonin, E. V. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00398-5 · Cited by 419
Cope, G. A., & Deshaies, R. J. (2003) · Cell · doi:10.1016/s0092-8674(03)00722-0 · Cited by 409
Wei, W., Jin, J., Schlisio, S., Harper, J. W., & Kaelin, W. G. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.005 · Cited by 403
Self-citationA superfamily of protein tags: ubiquitin, SUMO and related modifiers
Schwartz, D. C., & Hochstrasser, M. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00113-0 · Cited by 369
Duensing, S., & Münger, K. (2004) · International Journal of Cancer · doi:10.1002/ijc.11691 · Cited by 366
Skp2-Mediated Degradation of p27 Regulates Progression into Mitosis
Nakayama, K., Nagahama, H., Minamishima, Y. A., Miyake, S., Ishida, N., Hatakeyama, S., Kitagawa, M., Iemura, S.-I., Natsume, T., & Nakayama, K. I. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00131-5 · Cited by 364
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363
Nedd8 Modification of Cul-1 Activates SCFβTrCP-Dependent Ubiquitination of IκBα
Read, M. A., Brownell, J. E., Gladysheva, T. B., Hottelet, M., Parent, L. A., Coggins, M. B., Pierce, J. W., Podust, V. N., Luo, R.-S., Chau, V., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2326-2333.2000 · Cited by 363
Ruffner, H., Joazeiro, C. A. P., Hemmati, D., Hunter, T., & Verma, I. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081068398 · Cited by 359
Dehan, E., & Pagano, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.014 · Cited by 352
Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer
Al-Kuraya, K., Schraml, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1945 · Cited by 347
Diagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W., & Pavletich, N. P. (2003) · Molecules and Cells · Cited by 333
Self-citation"Covalent affinity" purification of ubiquitin-activating enzyme.
Ciechanover, A., Elias, S., Heller, H., & Hershko, A. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34957-3 · Cited by 320
Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1
Lois, L. M., & Lima, C. D. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600552 · Cited by 319
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 313
CAND1 Binds to Unneddylated CUL1 and Regulates the Formation of SCF Ubiquitin E3 Ligase Complex
Zheng, J., Yang, X., Harrell, J. M., Ryzhikov, S., Shim, E.-H., Lykke-Andersen, K., Wei, N., Sun, H., Kobayashi, R., & Zhang, H. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00784-0 · Cited by 308
Structural Basis of the Cks1-Dependent Recognition of p27Kip1 by the SCFSkp2 Ubiquitin Ligase
Hao, B., Zheng, N., Schulman, B. A., Wu, G., Miller, J. J., Pagano, M., & Pavletich, N. P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.09.003 · Cited by 301
Structural insights into the U-box, a domain associated with multi-ubiquitination
Ohi, M. D., Vander Kooi, C. W., Rosenberg, J. A., Chazin, W. J., & Gould, K. L. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb906 · Cited by 295
Degradation of p57 Kip2 mediated by SCF Skp2 -dependent ubiquitylation
Kamura, T., Hara, T., Kotoshiba, S., Yada, M., Ishida, N., Imaki, H., Hatakeyama, S., Nakayama, K., & Nakayama, K. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1831009100 · Cited by 292
Conformational Flexibility Underlies Ubiquitin Ligation Mediated by the WWP1 HECT Domain E3 Ligase
Verdecia, M. A., Joazeiro, C. A. P., Wells, N. J., Ferrer, J.-L., Bowman, M. E., Hunter, T., & Noel, J. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00774-8 · Cited by 283
Goldenberg, S. J., Cascio, T. C., Shumway, S. D., Garbutt, K. C., Liu, J., Xiong, Y., & Zheng, N. (2004) · Cell · doi:10.1016/j.cell.2004.10.019 · Cited by 280
Gewin, L., Myers, H., Kiyono, T., & Galloway, D. A. (2004) · Genes & Development · doi:10.1101/gad.1214704 · Cited by 277
U-box proteins as a new family of ubiquitin ligases
Hatakeyama, S., & Nakayama, K.-I. I. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00245-6 · Cited by 264
Talis, A. L., Huibregtse, J. M., & Howley, P. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6439 · Cited by 263
Tedesco, D., Lukas, J., & Reed, S. I. (2002) · Genes & Development · doi:10.1101/gad.1011202 · Cited by 261
Vousden, K. H., & Prives, C. (2005) · Cell · doi:10.1016/j.cell.2004.12.027 · Cited by 259
Genetic clues to the pathogenesis of Parkinson's disease
Vila, M., & Przedborski, S. (2004) · Nature Medicine · doi:10.1038/nm1068 · Cited by 255
Ciechanover, A., Elias, S., Heller, H., Ferber, S., & Hershko, A. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43856-8 · Cited by 253
MDM2 Is a Negative Regulator of p21 , Independent of p53
Zhang, Z., Wang, H., Li, M., Agrawal, S., Chen, X., & Zhang, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312264200 · Cited by 252
Molecular pathogenesis of Parkinson's disease
Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251
JAMM: A Metalloprotease-Like Zinc Site in the Proteasome and Signalosome
Ambroggio, X. I., Rees, D. C., & Deshaies, R. J. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0020002 · Cited by 247
Are ubiquitination pathways central to Parkinson’s disease?
Giasson, B. I., & Lee, V. M.-Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00509-9 · Cited by 234
The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications
Burger, A. M., & Seth, A. K. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.006 · Cited by 224
Structural Basis for Recruitment of Ubc12 by an E2 Binding Domain in NEDD8's E1
Huang, D. T., Paydar, A., Zhuang, M., Waddell, M. B., Holton, J. M., & Schulman, B. A. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.020 · Cited by 202
ErbB2 Degradation Mediated by the Co-chaperone Protein CHIP
Zhou, P., Fernandes, N., Dodge, I. L., Reddi, A. L., Rao, N., Safran, H., DiPetrillo, T. A., Wazer, D. E., Band, V., & Band, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209640200 · Cited by 200
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression
Kossatz, U., Dietrich, N., Zender, L., Buer, J., Manns, M. P., & Malek, N. P. (2004) · Genes & Development · doi:10.1101/gad.321004 · Cited by 194
Greene, J. C., Whitworth, A. J., Andrews, L. A., Parker, T. J., & Pallanck, L. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi074 · Cited by 194
SCF-mediated protein degradation and cell cycle control
Ang, X. L., & Wade Harper, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208614 · Cited by 193
Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain
Verma, R., Peters, N. R., D'Onofrio, M., Tochtrop, G. P., Sakamoto, K. M., Varadan, R., Zhang, M., Coffino, P., Fushman, D., Deshaies, R. J., et al. (2004) · Science · doi:10.1126/science.1100946 · Cited by 193
Genetics of Parkinsonʼs disease
Gasser, T. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000170951.08924.3d · Cited by 192
Stickle, N. H., Chung, J., Klco, J. M., Hill, R. P., Kaelin, W. G., & Ohh, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3251-3261.2004 · Cited by 185
Jones, D., Crowe, E., Stevens, T. A., & Candido, E. P. M. (2001) · Genome Biology · doi:10.1186/gb-2001-3-1-research0002 · Cited by 183
Gross-Mesilaty, S., Reinstein, E., Bercovich, B., Tobias, K. E., Schwartz, A. L., Kahana, C., & Ciechanover, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8058 · Cited by 177
The von Hippel–Lindau tumor suppressor protein: new insights into oxygen sensing and cancer
Kim, W., & Kaelin, W. G. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00010-2 · Cited by 175
Harnessing the Ubiquitination Machinery to Target the Degradation of Specific Cellular Proteins
Zhou, P., Bogacki, R., McReynolds, L., & Howley, P. M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00074-5 · Cited by 164
Fang, S., Lorick, K. L., Jensen, J. P., & Weissman, A. M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00095-0 · Cited by 163
Clinical profile of Angelman syndrome at different ages
Buntinx, I. M., Hennekam, R. C. M., Brouwer, O. F., Stroink, H., Beuten, J., Mangelschots, K., & Fryns, J. P. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560213 · Cited by 150
A unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8
Huang, D. T., Miller, D. W., Mathew, R., Cassell, R., Holton, J., Roussel, M., & Schulman, B. (2004) · Nature Structural &Molecular Biology · doi:10.1038/nsmb826 · Cited by 148
Gregori, L. L., Poosch, M. S., Cousins, G. D., & Chau, V. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38890-8 · Cited by 134
How does parkin ligate ubiquitin to Parkinson's disease? First in Molecular Medicine Review Series
Kahle, P. J., & Haass, C. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400188 · Cited by 133
parkin counteracts symptoms in a Drosophila model of Parkinson's disease
Haywood, A. F. M., & Staveley, B. E. (2004) · BMC Neuroscience · doi:10.1186/1471-2202-5-14 · Cited by 133
Rolfe, M., Beer‐Romero, P., Glass, S., Eckstein, J., Berdo, I., Theodoras, A. M., Pagano, M., & Draetta, G. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3264 · Cited by 129
Self-citationTherapeutic exploitation of the p53 pathway
Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127
Anglesio, M. S., Evdokimova, V. E., Melnyk, N., Zhang, L., Fernandez, C. V., Grundy, P. E., Leach, S. R., Marra, M. A., Brooks-Wilson, A. R., Penninger, J. M., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh215 · Cited by 123
Ubiquitin, proteasome and parkin
Tanaka, K., Suzuki, T., Hattori, N., & Mizuno, Y. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.026 · Cited by 123
Nakayama, T., Toguchida, J., Wadayama, B., Kanoe, H., Kotoura, Y., & Sasaki, M. S. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640511 · Cited by 122
Parkin Gene Therapy for α-Synucleinopathy: A Rat Model of Parkinson's Disease
Yamada, M., Mizuno, Y., & Mochizuki, H. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.262 · Cited by 116
Shim, E., Johnson, L. K., Noh, H. L., Kim, Y. J., Sun, H., Zeiss, C. J., & Zhang, H. (2003) · PubMed · Cited by 113
Cooper, E. M., Hudson, A. W., Amos, J., Wagstaff, J. E., & Howley, P. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401302200 · Cited by 107
Wang, H., Nan, L., Yu, D. S., Agrawal, S., & Zhang, R. (2001) · PubMed · Cited by 106
SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells
Bhattacharya, S., Garriga, J., Calbó, J., Yong, T., Haines, D. S., & Graña, X. (2003) · Oncogene · doi:10.1038/sj.onc.1206339 · Cited by 102
Parkin gene therapy for α-synucleinopathy : a rat model of Parkinson's disease
山田, 正. (2005) · Medical Entomology and Zoology · Cited by 101
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro
Krajewski, M., Ozdowy, P., D’Silva, L., Rothweiler, U., & Holak, T. A. (2005) · Nature Medicine · doi:10.1038/nm1105-1135 · Cited by 96
Mutation of hCDC4 Leads to Cell Cycle Deregulation of Cyclin E in Cancer
Reed, S. E., Spruck, C., Sangfelt, O., van Drogen, F., Mueller‐Holzner, E., Widschwendter, M., Zetterberg, A., & Reed, S. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3417 · Cited by 95
Zhang, R., Wang, H., & Agrawal, S. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332663 · Cited by 61
Mdm2 Mutant Defective in Binding p300 Promotes Ubiquitination but Not Degradation of p53
Zhu, Q., Yao, J., Wani, G., Wani, M. A., & Wani, A. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102634200 · Cited by 58
Jiang, F., Caraway, N. P., Li, R., & Katz, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208459 · Cited by 57
Therapeutic anti-cancer targets upstream of the proteasome
Nalepa, G. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00083-5 · Cited by 53
Self-citationInterwoven Ubiquitination Oscillators and Control of Cell Cycle Transitions
Ang, X. L., & Harper, J. W. (2004) · Science s STKE · doi:10.1126/stke.2422004pe31 · Cited by 51
Self-citationHarper, J. W. (2004) · Cell · doi:10.1016/j.cell.2004.06.015 · Cited by 45
Self-citationWilkinson, K. D. (2004) · Cell · doi:10.1016/j.cell.2004.12.001 · Cited by 39
CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer
Koh, M. S., Ittmann, M., Kadmon, D., Thompson, T. C., & Leach, F. S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.1.2290 · Cited by 26
Prasad, G., Wang, H., Agrawal, S., & Zhang, R. (2002) · PubMed · Cited by 25
E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes
Kim, Y., Cairns, M. J., Marouga, R., & Sun, L. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700623 · Cited by 24
Karlsson, G. B., Jensen, A., Stevenson, L. F., Woods, Y. L., Lane, D. P., & Sørensen, M. S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602143 · Cited by 14
Touati, E., Krin, E., Quillardet, P., & Hofnung, M. J. (1996) · Carcinogenesis · doi:10.1093/carcin/17.12.2543 · Cited by 12
Reply to 'NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro'
Grinkevich, V. V., Issaeva, N., Hossain, S., Pramanik, A., & Selivanova, G. (2005) · Nature Medicine · doi:10.1038/nm1105-1136 · Cited by 11
Harnessing the power of prevention: human papillomavirus vaccines
Mayeaux, E. J. (2006) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/01.gco.0000216316.10690.c6 · Cited by 6
Zn2+ Fingers and Cervical Cancer
Foster, S. A., & Phelps, W. C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.14.1180 · Cited by 2
Cited by
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationRevisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion
Wu, Y., & Zhou, B. P. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605530 · Cited by 798
Metadata
- Authors
- Nalepa, G., Rolfe, M., & Harper, J. W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-07-01
- Volume
- 5
- Issue
- 7
- Pages
- 596-613
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1603251764
- Cited by
- 608
- References
- 163
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.